Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

2017-12-14
Price :
Published : Dec-2017
No. of Pages : 58
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Astellas Pharma Expands Licensing Agreement with Cytokinetics 10
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 12
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor 14
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 15
Equity Offering 17
Cytokinetics Plans to Raise Funds through Public Offering of Securities 17
Cytokinetics Prices Public Offering of Shares for USD75 Million 18
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 20
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 21
Cytokinetics Completes Public Offering Of Shares For US$5 Million 23
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 24
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 26
Cytokinetics Completes Private Placement Of Common Stock For US$8 Million 28
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For US$12.1 Million 30
Cytokinetics Inc - Key Competitors 32
Cytokinetics Inc - Key Employees 33
Cytokinetics Inc - Locations And Subsidiaries 34
Head Office 34
Recent Developments 35
Strategy And Business Planning 35
Jan 11, 2016: Cytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio of Muscle Biology Drug Candidates 35
Financial Announcements 36
Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 36
Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 38
Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 40
Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 42
Oct 27, 2016: Cytokinetics Reports Third Quarter 2016 Financial Results 45
Jul 28, 2016: Cytokinetics Reports Second Quarter 2016 Financial Results 48
Apr 28, 2016: Cytokinetics Reports First Quarter 2016 Financial Results 50
Feb 16, 2016: Cytokinetics Reports Fourth Quarter 2015 Financial Results 52
Corporate Communications 55
May 20, 2016: Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors 55
Product News 56
Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 56
Clinical Trials 57
Nov 07, 2016: Cytokinetics Announces Publication Relating to Novel Smooth Muscle Myosin Inhibitor 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cytokinetics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Astellas Pharma Expands Licensing Agreement with Cytokinetics 10
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 12
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor 14
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 15
Cytokinetics Plans to Raise Funds through Public Offering of Securities 17
Cytokinetics Prices Public Offering of Shares for USD75 Million 18
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 20
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 21
Cytokinetics Completes Public Offering Of Shares For US$5 Million 23
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 24
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 26
Cytokinetics Completes Private Placement Of Common Stock For US$8 Million 28
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For US$12.1 Million 30
Cytokinetics Inc, Key Competitors 32
Cytokinetics Inc, Key Employees 33

List of Figures
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Filed in: Pharmaceutical
Publisher : GlobalData